
    
      This trial has been set up with two arms. Screened patients would be included into one of the
      arms based on tumor PD-L1 expression. The purpose of this study is to compare the efficacy of
      the approved checkpoint inhibitor pembrolizumab and home-made drug Sintilimab in patients
      with advanced NSCLC whose tumor have high PD-L1 expression and low or negative expression.
    
  